Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate Safety and Efficacy of ASC40 (Denifanstat) Tablets in Subjects With Moderate to Severe Acne Vulgaris

NCT06192264 is registered in ClinicalTrials.gov with Ascletis Pharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT06192264
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06192264 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate Safety and Efficacy of ASC40 (Denifanstat) Tablets in Subjects With Moderate to Severe Acne Vulgaris
Lead sponsor
Ascletis Pharmaceuticals Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
January 23, 2024
Completion date
May 19, 2025
Enrollment
480 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

acne